drugset
drugset / Trial / NCT00340327

Study Evaluating IMA-638 in Healthy Japanese

NCT00340327 ↗

Phase 1 Completed Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedSingle-groupDouble-blindDiagnostic

Summary

The purpose of this study is to evaluate the safety and drug levels for single, ascending doses of IMA-638 in healthy Japanese subjects.

Timeline

Start
2006-06
Primary completion
—
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Anrukinzumab Monoclonal antibody — —

Indications

No indication recorded.